+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Bioresorbable Polymers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 120 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292623
The bioresorbable polymers market size was valued at USD 1.82 billion in 2026 and is estimated to grow from USD 2.02 billion in 2027 to USD 3.50 billion by 2032, at a CAGR of 11.65% during the forecast period (2027-2032). This report is Segmented by Polymer Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Poly(Lactic-Co-Glycolic Acid) (PLGA), and More), Application (Orthopedic Devices, Drug Delivery, Cardiovascular Applications, Wound Care and Sutures, and More), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Bioresorbable Polymers Market Trends and Insights

Rising Orthopedic and Trauma Procedure Volumes

Orthopedic and trauma procedures remain the primary driver of demand for bioresorbable polymers, as temporary fixation devices can be resorbed once bone healing is complete. Rising geriatric populations and musculoskeletal disease rates support surgical procedure numbers. A 2025 review found that orthopedics accounted for 75% of surgical studies evaluating biodegradable polymer implants, underscoring the clinical role of resorbable materials in this specialty. The bioresorbable polymers market benefits from applications such as anterior cruciate ligament reconstruction, rotator cuff repair, and meniscal fixation. These procedures are also relevant for younger patients who may prefer to avoid retained hardware. This demand base supports the continued use of these materials in trauma and sports medicine devices.

Shift Toward Implant Systems That Avoid Removal Surgery

Permanent hardware can be associated with stress shielding, local tissue reactions, and revision procedures. Bioresorbable screws, pins, and plates are designed to degrade over months or years while mechanical load returns to healing tissue. A 2025 clinical study on absorbable cranial flap fixation reported a 100% success rate for bone flap positioning in the experimental group. The study also reported a residual implant volume of 48.80% at 48 weeks, indicating controlled degradation in the evaluated system. Avoiding a revision procedure can make these devices more attractive to hospital procurement teams, as readmissions add costs. The bioresorbable polymers market benefits from both clinical and economic interest in reducing the need for later interventions.

Long and Application-Dependent Validation Cycles

Bioresorbable medical devices require degradation kinetics studies, biocompatibility assessments, and clinical evidence, all of which vary by application. Cardiovascular devices face longer regulatory review than absorbable sutures due to higher clinical risk. The European Union Medical Devices Regulation mandates a comprehensive clinical evaluation for medical devices. Changes in molecular weight, copolymer ratio, or sterilization method can necessitate new biocompatibility work under ISO 10993 requirements. These steps extend development timelines and increase the burden on smaller innovators. The bioresorbable polymers market consequently favors suppliers with established material and regulatory records.

Other drivers and restraints analyzed in the report include:
  • Precision Controlled-Release Drug Delivery
  • Patient-Specific Devices Enabled by Additive Manufacturing
  • Degradation-Particle and Inflammatory-Risk Uncertainty

Segment Analysis

PLA held 35.83% of the bioresorbable polymers market share by polymer type in 2026. Its position reflects broad regulatory acceptance, a well-characterized degradation profile, and relevance for load-bearing orthopedic fixation. PLA is suitable for plates, screws, and suture anchors where resorption timelines of two years or longer are clinically appropriate. A 2025 review described the use of PLA in knee, shoulder, ankle, and foot fixation procedures. The material's crystallinity and slow degradation support its use in trauma and sports medicine. Ashland launched additional high-molecular-weight Viatel grades in June 2025 for orthopedic and drug delivery applications, indicating continued demand for premium medical-grade PLA.

PGA is forecast to expand at a 12.67% CAGR during 2027-2032 within the bioresorbable polymers market. It is used in sutures and shorter-cycle implants where 60- to 90-day resorption is preferred. Poly(lactic-co-glycolic acid) (PLGA) can degrade over a period of 2 months to more than 1 year by adjusting the lactide-to-glycolide ratio, supporting its use in drug delivery systems and cardiovascular scaffolding. Polycaprolactone (PCL) has a two- to four-year degradation period and a low melting point, which supports its use in dentistry and in blending with PLA composites. A 2025 spinal cage study used PLA/PCL blends to support the development of biodegradable, shape-memory devices. Polyhydroxyalkanoate (PHA) remains a relatively small material category, with interest in cardiovascular and tissue-engineering research, but it faces ongoing limitations related to production costs and mechanical strength. The differences among these polymers allow device developers to select a degradation period suited to a specific clinical purpose. PGA is suited to applications requiring faster absorption, while PLA supports longer-lasting fixation. PLGA offers adjustable degradation behavior for controlled release and scaffold design. PCL is used where processing behavior and slower degradation are valuable. This range of materials enables the bioresorbable polymers market to serve several device formats and treatment settings.

Complete Report Scope:

  • By Polymer Type
    • Polylactic Acid (PLA)
    • Polyglycolic Acid (PGA)
    • Poly(Lactic-co-Glycolic Acid) (PLGA)
    • Polycaprolactone (PCL)
    • Polyhydroxyalkanoates (PHA)
    • Others
  • By Application
    • Orthopedic Devices
    • Drug Delivery
    • Cardiovascular Applications
    • Wound Care and Sutures
    • Other Applications
  • By Geography
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • ASEAN Countries
      • Rest of Asia-Pacific
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • NORDIC Countries
      • Rest of Europe
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Middle East and Africa
      • Saudi Arabia
      • South Africa
      • Rest of Middle East and Africa

Geography Analysis

North America accounted for 32.45% of the bioresorbable polymers market share in 2026. The United States supports this position through high surgical numbers, established reimbursement for advanced medical devices, and Food and Drug Administration (FDA) pathways for polymer-containing devices. Quality-system requirements for implantable devices favor GMP-certified polymer suppliers, reinforcing the position of established specialty chemical companies with US production sites. Canada and Mexico remain smaller markets, though procedure growth in orthopedics and minimally invasive surgery supports demand. North America also benefits from active development in non-fixation orthopedic and drug delivery applications. The region provides a large base of hospitals and device developers with access to new resorbable products. While regulatory requirements can lengthen development timelines, they also create clear expectations for materials used in implantable devices. As a result, suppliers that maintain quality documentation and application support are well-positioned to serve customers in the region.

Europe is the second-largest regional market, led by Germany, the United Kingdom, France, and the Nordic countries. The region combines advanced bioresorbable polymer production with complex surgical procedures. Corbion operates PURASORB production facilities in Gorinchem, Netherlands, and Tucker, Georgia, supporting European and global supply. In July 2025, Evonik appointed IMCD as its exclusive European distributor for RESOMER bioresorbable polymers across the European Economic Area (EEA), the United Kingdom, Switzerland, and Turkey. The agreement covers orthopedic devices, tissue reconstruction, dental meshes, and 3D-printed implantable devices. Europe's position is further reinforced by the presence of manufacturers serving global device customers, and distribution arrangements extend access to qualified polymers beyond their production locations. The range of covered applications indicates that demand is not limited to a single implant type. South America, the Middle East, and Africa remain smaller markets where the development of surgical infrastructure, private hospital growth, and the procurement of biodegradable medical materials may support future demand. However, regulatory alignment with international standards remains a constraint in these regions.

Asia-Pacific is forecast to expand at a 12.81% CAGR through 2032, the fastest regional growth rate in the bioresorbable polymers market. China, Japan, South Korea, and India have different demand profiles but are all strengthening their medical device capabilities. China's Healthy China 2030 program and its 14th Five-Year Plan for bioeconomy development support domestic interest in medical-grade PLA, PLGA, and PGA. In July 2025, Evonik opened its largest medical device applications center in Shanghai, which includes an ISO Class 7 cleanroom for processing bioresorbable polymers for the pan-Asian market. Japan's aging population supports demand for orthopedic and cardiovascular devices. South Korea's regenerative medicine activity and India's investment in medical devices are also contributing to the development of biodegradable implants. China is significant in domestic medical and device production; Japan focuses on advanced care for an aging population; South Korea supports scaffold development through regenerative medicine; and India is building medical device manufacturing capacity. While these markets develop at different rates, each contributes a distinct source of demand, collectively supporting broader regional adoption of bioresorbable materials.


List of Companies Covered in this Report:

  • Ashland
  • Bezwada Biomedical, LLC
  • Biogeneral, Inc.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Corbion N.V.
  • dsm-firmenich
  • Elixir Medical Corporation
  • Evonik Industries AG
  • Geon Performance Solutions LLC
  • Johnson and Johnson MedTech
  • KLS Martin Group
  • Medtronic
  • Poly-Med Incorporated
  • REVA Medical, LLC
  • Seqens

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Orthopedic and Trauma Procedure Volumes
4.2.2 Shift Toward Implant Systems That Avoid Removal Surgery
4.2.3 Precision Controlled-Release Drug Delivery
4.2.4 Patient-Specific Devices Enabled by Additive Manufacturing
4.2.5 Expansion of Medical-Grade Polymer Capacity and CDMO Support
4.3 Market Restraints
4.3.1 Long and Application-Dependent Validation Cycles
4.3.2 Degradation-Particle and Inflammatory-Risk Uncertainty
4.3.3 Processing Sensitivity and Batch-to-Batch Consistency Risk
4.4 Value Chain Analysis
4.5 Porter’s Five Forces Analysis
4.5.1 Bargaining Power of Suppliers
4.5.2 Bargaining Power of Buyers
4.5.3 Threat of New Entrants
4.5.4 Threat of Substitutes
4.5.5 Competitive Rivalry
5 Market Size and Growth Forecasts (Value)
5.1 By Polymer Type
5.1.1 Polylactic Acid (PLA)
5.1.2 Polyglycolic Acid (PGA)
5.1.3 Poly(Lactic-co-Glycolic Acid) (PLGA)
5.1.4 Polycaprolactone (PCL)
5.1.5 Polyhydroxyalkanoates (PHA)
5.1.6 Others
5.2 By Application
5.2.1 Orthopedic Devices
5.2.2 Drug Delivery
5.2.3 Cardiovascular Applications
5.2.4 Wound Care and Sutures
5.2.5 Other Applications
5.3 By Geography
5.3.1 Asia-Pacific
5.3.1.1 China
5.3.1.2 India
5.3.1.3 Japan
5.3.1.4 South Korea
5.3.1.5 ASEAN Countries
5.3.1.6 Rest of Asia-Pacific
5.3.2 North America
5.3.2.1 United States
5.3.2.2 Canada
5.3.2.3 Mexico
5.3.3 Europe
5.3.3.1 Germany
5.3.3.2 United Kingdom
5.3.3.3 France
5.3.3.4 Italy
5.3.3.5 NORDIC Countries
5.3.3.6 Rest of Europe
5.3.4 South America
5.3.4.1 Brazil
5.3.4.2 Argentina
5.3.4.3 Rest of South America
5.3.5 Middle East and Africa
5.3.5.1 Saudi Arabia
5.3.5.2 South Africa
5.3.5.3 Rest of Middle East and Africa
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share (%)/Ranking Analysis
6.4 Company Profiles (includes Global Overview, Market Overview, Core Segments, Financials as available, Strategic Information, Products and Services, and Recent Developments)
6.4.1 Ashland
6.4.2 Bezwada Biomedical, LLC
6.4.3 Biogeneral, Inc.
6.4.4 Biotronik SE & Co. KG
6.4.5 Boston Scientific Corporation
6.4.6 Corbion N.V.
6.4.7 dsm-firmenich
6.4.8 Elixir Medical Corporation
6.4.9 Evonik Industries AG
6.4.10 Geon Performance Solutions LLC
6.4.11 Johnson and Johnson MedTech
6.4.12 KLS Martin Group
6.4.13 Medtronic
6.4.14 Poly-Med Incorporated
6.4.15 REVA Medical, LLC
6.4.16 Seqens
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ashland
  • Bezwada Biomedical, LLC
  • Biogeneral, Inc.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Corbion N.V.
  • dsm-firmenich
  • Elixir Medical Corporation
  • Evonik Industries AG
  • Geon Performance Solutions LLC
  • Johnson and Johnson MedTech
  • KLS Martin Group
  • Medtronic
  • Poly-Med Incorporated
  • REVA Medical, LLC
  • Seqens